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Antibiotic treatment of tularaemia is based on a few drugs, including the fluoroquinolones
(e.g., ciprofloxacin), the tetracyclines (e.g., doxycycline), and the aminoglycosides
(streptomycin and gentamicin). Because no effective and safe vaccine is currently
available, tularaemia prophylaxis following proven exposure to F. tularensis also relies on
administration of antibiotics. A number of reasons make it necessary to search for new
therapeutic alternatives: the potential toxicity of first-line drugs, especially in children and
pregnant women; a high rate of treatment relapses and failures, especially for severe
and/or suppurated forms of the disease; and the possible use of antibiotic-resistant strains
in the context of a biological threat. This review presents novel therapeutic approaches
that have been explored in recent years to improve tularaemia patients’ management and
prognosis. These new strategies have been evaluated in vitro, in axenic media and cell
culture systems and/or in animal models. First, the activities of newly available antibiotic
compounds were evaluated against F. tularensis, including tigecycline (a glycylcycline),
ketolides (telithromycin and cethromycin), and fluoroquinolones (moxifloxacin, gatifloxacin,
trovafloxacin and grepafloxacin). The liposome delivery of some antibiotics was evaluated.
The effect of antimicrobial peptides against F. tularensis was also considered. Other drugs
were evaluated for their ability to suppress the intracellular multiplication of F. tularensis.
The effects of the modulation of the innate immune response (especially via TLR
receptors) on the course of F. tularensis infection was characterized. Another approach
was the administration of specific antibodies to induce passive resistance to F. tularensis
infection. All of these studies highlight the need to develop new therapeutic strategies
to improve the management of patients with tularaemia. Many possibilities exist, some
unexplored. Moreover, it is likely that new therapeutic alternatives that are effective
against this intracellular pathogen could be, at least partially, extrapolated to other human
pathogens.
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INTRODUCTION
Francisella tularensis, the agent of tularaemia, is a facultative intra-
cellular pathogen of humans and hundreds of animal species
(including mammals, insects, arthropods, and protozoa). It is
highly infectious, with only 10 bacteria able to cause a lethal infec-
tion. Two F. tularensis subspecies are virulent for humans: subsp.
tularensis (type A), found mainly in North America, and subsp.
holarctica (type B), found throughout the northern hemisphere.
Both subspecies are classified as category A agents of biological
threat by the Centers for Disease Control (CDC, Atlanta, Georgia,
USA).
Tularaemia is considered a re-emerging disease, and recent
outbreaks have been reported worldwide (Chitadze et al., 2009;
Hauri et al., 2010). The mean incubation period of tularaemia
is only 3–5 days (Tarnvik and Chu, 2007) and even less in case
of aerosol contamination. Most clinical cases involve chronic
lymphadenopathy associated with a skin, mucosa or conjunc-
tival inoculation lesion. Less frequently, patients suffer from
systemic diseases, and inhalation of infected aerosols may lead
to severe pneumonia with mortality rates up to 60% (Gill and
Cunha, 1997). This latter clinical form is the most feared in
the context of bioterrorism. No vaccine is currently available
and only a few antibiotic classes are effective to treat tularaemia
patients, including the fluoroquinolones, the tetracyclines and the
aminoglycosides (only streptomycin and gentamicin) (KuoLee
and Chen, 2007; Hepburn and Simpson, 2008). Although no
acquired resistance to these antibiotics has been described in nat-
ural strains of F. tularensis, many therapeutic failures and relapses
have been reported (Perez-Castrillon et al., 2001; Kosker et al.,
2013). Even with antibiotic treatment, tularaemia may be asso-
ciated with 2% mortality (Evans et al., 1985). It is therefore
essential to develop novel and effective preventive and curative
treatments.
We will review the current therapeutic approaches and
new therapeutic strategies (Table 1) published in the English
literature.
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Table 1 | New therapeutic alternatives evaluated against F. tularensis infection.
Drug Mechanism of action/target Activity on F. tularensis References
NEW ANTIBIOTICS
Ketolides Inhibit protein synthesis by interacting with the
peptidyl-transferase site of the bacterial 50S
ribosomal subunit.
Effective in vitro against French isolates of
F. tularensis subsp. holarctica
Gestin et al., 2010
Tigecycline Inhibits protein translation by binding to the
30S ribosomal subunit and blocking entry of
amino-acyl tRNA molecules into the A site of
the ribosome
Effective in vitro against Hungarian F. tularensis
subsp. holarctica
Kreizinger et al.,
2013b
Grepafloxacin
Trovafloxacin
Sparfloxacin
Gatifloxacin
Inhibit DNA synthesis by targeting DNA gyrase
and topoisomerases
Highly active in vitro against American and
Austrian F. tularensis subsp. tularensis and
subsp. holarctica strains
Gatifloxacin effective in vivo in a BALB/c
mouse model of F. tularensis Schu S4 infection
Ikaheimo et al., 2000
Johansson et al.,
2002
Tomaso et al., 2005
Piercy et al., 2005;
Steward et al., 2006
Linezolide Inhibits the initiation process of protein
synthesis
Effective in vitro against Turkish strains,
Not effective against F. tularensis strains
isolated in Hungary or in North America
Yesilyurt et al., 2011
Johansson et al.,
2002
ANTIMICROBIAL PEPTIDE
LL-37 Stimulates the innate immune response,
increases in the production of IL-6, Il-12,
IFN-gamma, and MCP-1
Moderately and transiently effective in a
murine model of LVS-induced pneumonia
Flick-Smith et al.,
2013
OTHER MODULATOR OF INNATE IMMUNE RESPONSE
IL-12 Activates Th1 and NK cells and induces the
production of IFN-gamma
Improves the clinical outcome and survival of
animals infected with F. novicida, when
co-administrated with gentamicin.
Pammit et al., 2004
Kirimanjeswara
et al., 2008
AGP Synthetic TLR4 agonist, increases the amount
of intrapulmonary cytokines and chemokines
Reduced bacterial replication in the lungs, liver
and spleen, and increased survival of animals
infected with F. novicida
Lembo et al., 2008
CpG TLR9 activator, indirectly activates NK cells
resulting in cytokines and NO production
Better survival of mice infected with F.
tularensis LVS, but no effect in mice with F.
tularensis SCHU4 pneumonia
Elkins et al., 2009
Rozak et al., 2010
poly(I:C) Synthetic double stranded RNA analog, TLR3
activator, induces an early and effective innate
immune response
Better survival of mice infected with F.
tularensis LVS or Schu S4
Reduction in replication of F. tularensis within
human monocyte-derived macrophages
Pyles et al., 2010
Galantamine Influences the immune response via the
cholinergic anti-inflammatory pathway by
up-regulating IFN-gamma production and
down-regulating IL-6 production
Reduced mortality rates in mice infected with
F. tularensis LVS
Pohanka et al., 2012
Acai PS Enhances Th1 cell-related immunity Increased survival of mice infected with F.
tularensis Schu S4
Skyberg et al., 2012
SPECIFIC ANTIBODIES
Monoclonal
antibodies
Monoclonal antibodies against the LPS of F.
tularensis LVS
Successfully used to treat LVS-induced
pneumonia; No effect on mice infected with F.
tularensis Schu S4
Lu et al., 2007
Kirimanjeswara
et al., 2008
Savitt et al., 2009
(Continued)
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Table 1 | Continued
Drug Mechanism of action/target Activity on F. tularensis References
Immune
sera
Immune sera from mice infected via intra-nasal
Schu S4 challenge, and then treated with
levofloxacin
Sera containing abundant immunoglobulin
IgG2a
Protective in mice infected with F. tularensis
Schu S4, when administered 24 h
post-infection
Klimpel et al., 2008
Anti-MPF
IgM and IgG
antibodies
Antibodies directed against the membrane
protein fraction (MFP) of F. tularensis Schu S4
Successfully used to treat mice infected with
F. tularensis Schu S4 when combined with
gentamicin
Sutherland et al.,
2012
RECOMMENDED ANTIBIOTICS FOR TULARAEMIA
TREATMENT (WHO GUIDELINES)
According to the WHO guidelines (WHO, 2007), patients with
severe tularaemia requiring hospitalization should receive par-
enteral administration of streptomycin or gentamicin. Both
aminoglycosides display in vitro bactericidal activity against F.
tularensis types A and B (Enderlin et al., 1994; Johansson et al.,
2002; Kreizinger et al., 2013b). Aminoglycosides are associated
with better outcomes and lower relapse rates (Enderlin et al.,
1994). However, they can only be used parenterally, and they are
occasionally associated with severe toxicity (especially ototoxicity
and nephrotoxicity). Streptomycin is no longer available in many
countries.
Fluoroquinolones are now advocated as first-line drugs in
patients with clinical manifestations of mild to moderate sever-
ity (Ellis et al., 2002; Johansson et al., 2002). Ciprofloxacin may
be given intravenously or by oral administration. In vitro, flu-
oroquinolones are highly active against F. tularensis subsp. hol-
arctica (Syrjala et al., 1991; Scheel et al., 1993; Ikaheimo et al.,
2000; Kreizinger et al., 2013b) and F. tularensis subsp tularensis
(Johansson et al., 2002). Most data are restricted to ciprofloxacin,
but levofloxacin, with an oral bioavailability of over 99% and daily
administration, is an attractive alternative. Murine models have
shown that the intraperitoneal administration of levofloxacin is
100% effective in preventing tularaemia after F. tularensis chal-
lenge (Klimpel et al., 2008). Intravenous administration of lev-
ofloxacin was also successful in treating human tularaemia cases,
without relapse (Limaye and Hooper, 1999; Aranda, 2001). The
bioavailability and efficacy of levofloxacin against F. tularensis
was also studied in a common marmoset model of inhalational
tularaemia that more faithfully mimics human tularaemia pneu-
monia (Nelson et al., 2010). Orally administered levofloxacin
was highly effective in preventing the onset of acute inhala-
tion tularaemia. Meric et al. also reported that moxifloxacin
was as successful as ciprofloxacin for treatment of oropharyngeal
tularaemia (Meric et al., 2008). Recently, Sutera et al. obtained
in vitro mutants highly resistant to fluoroquinolones in different
Francisella species (F. tularensis subsp. holarctica LVS, F. novi-
cida, and F. philomiragia) by propagating strains with increasing
concentration of ciprofloxacin. All high-level resistant mutants
shared cross-resistance to other fluoroquinolones tested (mox-
ifloxacine and levofloxacine), while some also revealed striking
levels of cross-resistance to other clinically relevant antibiotic
classes (the aminoglycoside gentamicin and tetracyclines) (Sutera
et al., 2014).
Tetracyclines, especially doxycycline, are considered a potential
alternative. However, due to its bacteriostatic activity, treatment
must be administrated for a minimum of 2 weeks, and higher
relapse rates have been reported as compared to fluoroquinolones
(Enderlin et al., 1994). Tetracyclines are classically contraindi-
cated in children less than 8 years old because of the risk of teeth
discoloration, and in pregnant women because of foetal bone
toxicity.
Whatever drug is administered, failures and relapses are often
associated with delayed and/or insufficiently long treatment.
Suppurated lymph nodes often need to be removed surgically
to obtain clinical cure (Penn and Kinasewitz, 1987; Celebi et al.,
2006).
OTHER ANTIBIOTICS
Most beta-lactams have no bacteriostatic activity against F.
tularensis in vitro (Tarnvik and Chu, 2007). Although third-
generation cephalosporins (e.g., ceftriaxone) may be active
in vitro against specific F. tularensis strains (Tomaso et al., 2005),
therapeutic failures with these antibiotics are common (Cross and
Jacobs, 1993). The ineffective activity of the beta-lactams against
F. tularensis may be related both to the secretion of a class A beta-
lactamase by this bacterium (Antunes et al., 2012) and to the
poor penetration of these antibiotics in eukaryotic cells (Maurin
et al., 2000). Thus, the beta-lactams are considered unreliable for
tularaemia treatment.
It was first assumed that North American isolates of F.
tularensis were naturally susceptible to macrolides, whereas most
European strains were naturally resistant, including the vaccine
strain F. tularensis LVS (Kudelina and Olsufiev, 1980). Later,
Georgi et al. showed that F. tularensis subsp. holarctica isolates
could be split into two biovars according to natural susceptibility
or resistance to erythromycin. Strains with high-level resistance
to erythromycin (i.e., biovar II) have spread to the northern
and eastern parts of Europe (including Scandinavia, the Balkans,
etc.), but also to Asia. The macrolide-susceptible strains (i.e.,
biovar I) predominate in western and southern Europe (France,
Switzerland, Spain) and in North America. There is an overlap
in the geographical distributions of both types of biovars, such
as in Germany (Georgi et al., 2012). Nevertheless, failures and
relapses in tularaemia patients treated with a macrolide have been
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reported worldwide, including in France (Maurin et al., 2011).
Note that all isolates tested by Garcia del Blanco et al. during
an outbreak in Spain were resistant to erythromycin (Garcia del
Blanco et al., 2004). Thus, erythromycin is not a reliable option
for treatment of tularaemia. Azithromycin is more active in vitro
and has recently been proposed as a possible alternative in preg-
nant women in areas where the susceptible type B biovar I strains
predominate (Dentan et al., 2013).
Although F. tularensis strains are susceptible to rifampicin
in vitro (Tomaso et al., 2005), this antibiotic is not recommended
for treatment of tularaemia because of a high risk of emergence
of resistance during therapy. Chloramphenicol is less effective
in vitro against F. tularensis, and it is associated with high relapse
rates as well as bone marrow toxicity (Enderlin et al., 1994;
Ikaheimo et al., 2000).
NEW ANTIBIOTICS
Ketolides
The ketolide compounds (telithromycin and cethromycin) are
a subclass of macrolide antibiotics, which have been designed
to address the problem of macrolide resistance in respiratory
pathogens such as Streptococcus pneumoniae. Telithromycin was
more effective in vitro against French isolates of F. tularen-
sis subsp. holarctica than erythromycin (Gestin et al., 2010).
Cethromycin has comparable tissue penetration, pharmacoki-
netics and in vitro activity to telithromycin, especially against
bacterial species responsible for community-acquired pneumo-
nia (Hammerschlag and Sharma, 2008). Compared with other
macrolides, these compounds have different advantages, includ-
ing a higher affinity for the 50S ribosomal subunit and a better
stability at acidic pH (Hammerschlag and Sharma, 2008), which
may partly explain the better activity in the intracellular envi-
ronment of phagocytic cells where F. tularensis multiplies. Both
telithromycin and cethromycin are potential alternatives for treat-
ment of F. tularensis infection, but their clinical use in tularaemia
patients has never been reported. Some authors have emphasized
that cross-resistances betweenmacrolide compounds may rapidly
occur (Georgi et al., 2012).
Glycylcyclines
Tigecycline reaches high intracellular concentrations in tissues,
macrophages and neutrophils, which makes this agent an inter-
esting alternative for the treatment of intracellular pathogens
(Pankey, 2005). Two papers report that F. tularensis strains
isolated in Hungary and in Turkey were susceptible to tige-
cycline (Yesilyurt et al., 2011; Kreizinger et al., 2013a). These
in vitro data suggest the potential usefulness of this antibiotic in
tularaemia patients, but further in vivo experiments are needed
for confirmation.
New fluoroquinolones
Ikäheimo et al. evaluated the in vitro antimicrobial susceptibility
of 38 type B strains of F. tularensis isolated from human samples
and dead wild animals. Ciprofloxacin, levofloxacin, grepafloxacin,
and trovafloxacin had similar low MICs (Ikaheimo et al., 2000).
Johansson et al. (Johansson et al., 2002) showed that gatifloxacin,
grepafloxacin and sparfloxacin, were highly active against types
A and B strains of F. tularensis isolated in different regions
of the US. An Austrian study tested the susceptibility of 50 F.
tularensis strains mainly isolated from hares to a wide range of
antibiotics. The results showed low MIC values for all six flu-
oroquinolones tested (ciprofloxacin, levofloxacin, moxifloxacin,
gatifloxacin, sparfloxacin) (Tomaso et al., 2005). The in vivo
efficacy of gatifloxacin compared with ciprofloxacin and moxi-
floxacin was assessed in a BALB/c mouse model of F. tularensis
Schu S4 infection. Lower mortality rates were found for gati-
floxacin and moxifloxacin as compared to ciprofloxacin (Piercy
et al., 2005; Steward et al., 2006).
Linezolid
Although linezolid is used for treatment of infections caused by
Gram-positive bacteria, a Turkish study showed that F. tularensis
could be susceptible to linezolid in vitro (Yesilyurt et al., 2011).
However, linezolid was not effective against F. tularensis strains
isolated in Hungary and North America (Johansson et al., 2002).
Liposome delivery of antibiotics
Treatment failures and relapses may also be related to the poor
penetration and accumulation of antibiotics in tissues, especially
in the subcellular compartment where F. tularensis multiplies.
The liposome formulation of antibiotics is usually more effective
than the conventional formulations against intracellular bacteria
(Conley et al., 1997). Two studies have evaluated the liposome
delivery of fluoroquinolones in order to reach high therapeu-
tic doses of antibiotics within the intracellular compartment.
One study demonstrated the efficacy of liposome-encapsulated
ciprofloxacin, delivered to the lungs through aerosol inhala-
tion, in mice with F. tularensis pneumonia (Conley et al., 1997).
Another study showed that IV injection of liposome-encapsulated
ciprofloxacin resulted in higher serum levels of this antibiotic,
as well as increased drug retention in lungs, liver and spleen
compared with the free drug. They also confirmed that aerosol
inhalation of liposome-encapsulated ciprofloxacin, given for pro-
phylactic or therapeutic purposes, provided mice with complete
protection against a lethal F. tularensis pulmonary infection
(Wong et al., 2003). The enhanced therapeutic efficacy can be
attributable to the increased retention of ciprofloxacin in the
lungs and to better intracellular delivery of ciprofloxacin by lipo-
somes (Wong et al., 2003). The major drawback of this new
therapeutic strategy is the need for more efficient techniques for
preparing liposomal nanoparticles with great potential in target-
ing of antibiotics to bacteria and with high safety for humans
(Hallaj-Nezhadi and Hassan, 2013).
ANTIMICROBIAL PEPTIDES
The human cathelicidin antimicrobial peptide LL-37 provides
protection through host immunomodulation. It selectively reg-
ulates gene activation for expression of cytokines, chemokines
and their receptor to control the recruitment of leukocytes to
the infection site (Scott et al., 2002). It also activates or blocks
TLR signaling (Into et al., 2010) and modulates apoptosis in
neutrophils and epithelial cells (Barlow et al., 2011). Flick et al.
evaluated the protective effect of LL-37 against F. tularensis LVS
infection in cell culture and murine models. The objective was
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to overcome the immunosuppressive effects of F. tularensis infec-
tion by stimulating the innate immune response. Following LVS
intranasal challenge in mice, the administration of LL-37 resulted
in an increased production of IL-6, Il-12, IFN-gamma, and MCP-
1, and thereby reduced proliferation of bacteria in the lungs
48–72 h post-challenge. However, LL-37 was only moderately and
transiently effective, and mice ultimately succumbed to infection.
The immune potentiating activity of LL-37 suggests it could be
used as an adjunct therapy in the treatment of persistent forms of
tularaemia (Flick-Smith et al., 2013).
MODULATION OF THE INNATE IMMUNE RESPONSE AND
SUPPRESSION OF F. TULARENSIS REPLICATION
The pathogenicity of F. tularensis is correlated with its ability
to evade or suppress the activation of the host immune sys-
tem, and to replicate in phagocytic cells (Bosio et al., 2007). The
rapid induction of the innate immune response is critical in con-
trolling the early spread of intracellular pathogens. IFN-gamma
and TNF-alpha can activate macrophages in vitro to restrict the
replication of F. tularensis (Skyberg, 2013). IL-12 and Toll-like
receptor (TLR) signaling are also involved in IFN-gamma and
TNF-alpha production. One possible way to improve the efficacy
of tularaemia treatment, and reduce the dosage and duration of
the antibiotic treatment, is to combine cytokines with first-line
antibiotic drugs. Indeed, different studies support the hypothesis
that increasing the production of pro-inflammatory cytokines at
the early stage of infection can be beneficial. This review focuses
on immune agonists that, when administered after F. tularensis
challenges, prevent or attenuate the consequences of infection
and thus could be used as a curative therapeutic adjuvant in
tularaemia patients. Prophylactic aspects have been presented in
other reviews (KuoLee and Chen, 2007; Hepburn and Simpson,
2008; Skyberg, 2013). This approach has been used successfully
by Pammit et al. (2004), who showed that although IL-12 alone
was not able to reduce bacterial burdens in mice infected with
F. novicida, intranasal IL-12 treatment decreased spleen and liver
bacterial burdens more than 100-fold and lung bacterial burdens
50-fold when co-administrated with gentamicin. This combina-
tion improved clinical outcome and survival of animals when
administrated early (8–24 h) after infection (Pammit et al., 2004).
It should be mentioned that results obtained with F. novicida, a
highly virulent bacterium in mice but non-virulent in humans,
perhaps cannot be extrapolated to human infections caused by
F. tularensis. Treatment of mice with IL-12 resulted in an early
IFN-gamma response that allows the recruitment of neutrophils
to the lungs during the first 24 h of infection. Neutrophils con-
tribute to the rapid clearance of bacteria (Kirimanjeswara et al.,
2008).
The activation of TLR signaling pathways in phagocytic
cells has been reported to be a major defence mechanism
against Francisella infection (Cowley and Elkins, 2011). Lembo
et al. demonstrated that intranasal administration of a synthetic
TLR4 agonist (aminoalkyl glucosaminide phosphatase, AGP)
increased intrapulmonary cytokine and chemokine production.
Mice treated with AGP after F. novicida inhalation exhibited
reduced bacterial replication in the lung, liver and spleen, and
increased survival (Lembo et al., 2008).
Administration of bacterial or oligonucleotide DNA con-
taining CpG motifs to mice induced an immune activation
and effective protection against a lethal parenteral challenge of
these animals with F. tularensis LVS. This protection was highly
dependent on B lymphocyte cells and INF-gamma production.
Furthermore, animals surviving this lethal challenge developed
a pathogen-specific secondary immunity (Elkins et al., 1999).
More recently, these authors showed that DNA-related protection
against LVS infection was dependent on TLR9, which is expressed
intracellularly in murine macrophages, dendritic cells and B cells.
Surprisingly, their data indicated that the role of B cells was not
related to the action of CpG DNAmotifs but to the anti-LPS anti-
body production by these cells in the peritoneal cavity. Instead,
the production of solublemediators by NK cells primed with CpG
DNA in vivo contributed to DNA-mediated protection. Because
murine NK cells do not express TLR9, in vivo activation was indi-
rect and may have involved dendritic cells. In conclusion, this
study suggested that indirect activation of NK cells by CpG DNA,
via a TLR9-dependent pathway, resulted in the production of
cytokines and NO, which controlled the intracellular growth of F.
tularensis LVS in infected mice (Elkins et al., 2009). More recently,
Rozak et al. conducted the same experiment with the more viru-
lent SCHU4 strain. Their results revealed that CpG DNA failed
to positively affect the course of F. tularensis SCHU4 pneumonic
infection in mice (Rozak et al., 2010). These contradictory data
emphasize the need for evaluation of both type A and type B F.
tularensis strains in animal models.
Pyles et al. (2010) evaluated the effect of poly(I:C) (polyi-
nosine polycytosine), a synthetic double-stranded RNA analog
that stimulates TLR3, as a novel treatment for F. tularensis res-
piratory infection. TLR3 is expressed by respiratory epithelial
cells and macrophages and can trigger the induction of the host
innate immune response, including TNF-alpha, IFN-gamma, IL-
8, and IL-6 secretion. Intranasal administration of poly(I:C) in
mice induced an early and effective innate immune response by
increasing the secretion of cytokines and the neutrophil influx in
the lungs. This effect was transient but prolonged the survival
of animals. Furthermore, poly(I:C) increased cytokine secre-
tion by human monocyte-derived macrophages and significantly
reduced intracellular replication of F. tularensis in these cells.
Thus, Poly(I:C) may be a useful additive therapeutic agent in
patients infected by F. tularensis aerosols.
Galantamine is an inhibitor of acetyl-cholinesterase used for
treatment of Alzheimer’s disease. Galantamine has also been
reported to modify TNF-alpha levels through stimulation of the
cholinergic anti-inflammatory pathway (Liu et al., 2010). The
resolution of tularaemia infection is mediated by the produc-
tion of IFN-gamma and the activation of macrophages, result-
ing in an increased production of nitric oxide synthase and
killing of F. tularensis by these phagocytic cells. Pohanka et al.
(2012) showed that galantamine could significantly influence the
immune response via the cholinergic anti-inflammatory pathway
by up-regulating IFN-gamma production and down-regulating
IL-6 production. Mice treated with galantamine showed lower
mortality rates when infected with F. tularensis.
Skyberg et al. (2012) reported that a natural polysaccha-
ride extract isolated from Acai berry (Acai PS, derived from
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the berry of the palm tree Euterpe oleracea in South America)
enhanced the clearance of F. tularensis LVS and Schu4 from
human macrophages when co-cultured with autologous natu-
ral killer cells. Impaired replication of F. tularensis in human
macrophages was related to increased production of IFN-gamma
by NK cells. Intranasal administration of Acai PS tomice immedi-
ately, 24 or 48 h after a Schu4 aerosol challenge resulted in survival
rates of 73, 60, and 33%, respectively. In both human and murine
cells, Acai PS enhanced Th1 cell-mediated immunity. Acai PS is
currently the most active immunotherapeutic agent reported in
the literature for treatment of experimental pneumonia caused
by type A F. tularensis.
The activation of the innate immunity may help antibio-
therapy to eradicate F. tularensis in infected patients. However,
activation of the innate immunity may lead to higher inflam-
matory response and injury of the lung tissue. The timing of
administration of proinflammatory treatments requires careful
management, since there is a danger that their use may exacer-
bate the symptoms of disease in infected patients (D’Elia et al.,
2013). If treatment is initiated either just before or the same time
as infection, then the induction of proinflammatroy cytokines by
stimulatory molecules has beneficial effects on host survival as
shown with CpG oligonucleotides (Elkins et al., 1999). Moreover,
the mode of administration of such combination in humans
remains to be determined. The small window for such treat-
ment greatly limits application of this adjunctive therapy in
clinical practice. It has been observed that the use of proinflam-
matory cytokines themselves such as IL-1β cause side effects,
including generalized fatigue, headache, nausea, vomiting, myal-
gia, and arthralgia (Crown et al., 1991). By modulating rather
than up-regulating the immune response via mechanisms such
as cholinergic anti-inflammatory pathways (example of galan-
tamine, Pohanka et al., 2012), the damaging cytokine storms can
be prevented. This may allow a longer window for diagnosis and
treatment (D’Elia et al., 2013) but these strategies require more
in vivo investigation for further evaluation of their efficacy and
tolerance.
ADMINISTRATION OF SPECIFIC ANTIBODIES
Before the antibiotic era, patients suffering from tularaemia were
successfully treated with xenogeneic immune sera (Elkins et al.,
2007). The role of antibodies for protection against infections
caused by intracellular pathogens has long been controversial,
but recent studies have shown that they contribute to protec-
tion against F. tularensis infection (Kirimanjeswara et al., 2008;
Skyberg, 2013). Kirimanjeswara et al. showed that passive intra-
peritoneal transfer of immune serum in mice provided complete
protection against intranasal challenge with lethal doses of LVS,
even when administrated 24–48 h post-infection. These results
indicate that serum antibodies may be used for both prophylactic
and therapeutic purposes (Kirimanjeswara et al., 2007). Another
study showed that monoclonal antibodies against the LPS of F.
tularensis LVS could be successfully used to treat LVS-induced
pneumonia (Lu et al., 2007). Unfortunately, these promising
results could not be reproduced when using a F. tularensis type
A strain. Anti-LVS antibodies failed to protect mice challenged
with F. tularensis Schu S4. One explanation could be that the
Schu S4 strain completely abolished the inflammatory responses
that are required for efficient antibody-mediated bacterial clear-
ance (Kirimanjeswara et al., 2008). Another study also showed
relative efficacy for immunotherapy using monoclonal antibodies
(MAbs). Most particularly, MAbs directed against LVS compo-
nents could confer protection in mice challenged with this strain.
However, MAbs were much less active in protecting mice chal-
lenged with the type A F. tularensis Schu S4 strain (Savitt et al.,
2009). Klimpel et al. showed that mice infected via intra-nasal
Schu S4 challenge and then treated with levofloxacin developed
protective immunity. Interestingly, sera from these mice were
protective when passively transferred to naive mice, even when
administered 24 h post-infection. In these protective sera, the
most abundant immunoglobulin class was IgG2a, suggesting that
a Th1-type immune response was predominant (Klimpel et al.,
2008). Sutherland et al. showed that the passive transfer of anti-
bodies directed against the membrane protein fraction (MFP)
of F. tularensis Schu S4, to mice infected with the same strain,
resulted in complete protection when combined with gentam-
icin treatment. These sera contained high titers of anti-MPF IgM
and IgG antibodies, comparable to those observed during nat-
ural infection. Post-exposure immunization with MPF antigens
was an effective means of enhancing the activity of conventional
antimicrobial therapy for pneumonic tularaemia (Sutherland
et al., 2012). Immune sera are probably not effective enough to
treat severe pulmonary tularaemia cases, but could be used in
combination with antibiotics to obtain a more rapid response to
treatment.
CONCLUSION
The fear of a bioterrorism attack scenario after the September 11,
2001, incident has renewed the medical and scientific interest in
F. tularensis, a class A bioterrorism agent. However, only limited
progress has been made in the development of new tularaemia
therapies. Due to the lack of an effective and safe vaccine, antibi-
otics remain the only strategies available for prophylaxis and
treatment of tularaemia. New therapeutic alternatives are needed
because of the potential toxicity of first-line drugs, especially in
children and pregnant women; high rates of treatment relapses
and failures, especially for severe and/or suppurated forms of
the disease; and the possible use of antibiotic-resistant strains
in the context of biological threat. Among the new therapeu-
tic strategies, no published study present large-scale screening of
new molecules for inhibitory potential of F. tularensis growth.
There is no more data in the literature concerning the use of bac-
teriophage against Francisella. Activation of the innate immune
system can enhance resistance of the host to F. tularensis infec-
tion and could help clearance of the bacteria and disease cure
when combined with the administration of antibiotics. Promising
results have been obtained in animal models, but this strategy
only applies if the involved F. tularensis strain is still suscepti-
ble to antibiotics, which may not be the case in the context of
bioterrorism. Several virulence factors have been identified such
as the pathogenicity island but also genes encoding type IV pili, a
type II secretion system, a type VI secretion system, iron acquisi-
tion systems (Larsson et al., 2005). Bacterial virulence factors have
been increasingly regarded as attractive targets for development of
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novel antibacterial agents. This type of approach has for example
been used in Salmonella enterica serovar Typhimurium and led
to the identification of Cytosporone B, an inhibitor of the Type
III Secretion System of Salmonella as novel antibacterial agent
(Li et al., 2013). Finally, it should be remembered that new anti-
infective strategy effective against type B strains may not apply to
the more severe infections caused by type A strain.
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